MonoSol Rx Granted U.S. Article of Manufacture Patent

Patent Addresses Use of Thin Film to Deliver Drugs and Vitamins via Pacifier or Porous Nipple

Warren, NJ (April 2, 2009) – MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in dissolving thin film pharmaceutical products, today announced that it has been granted U.S. Patent No. 7,500,984 from the United States Patent and Trademark Office (USPTO). The patent relates to the delivery of an active ingredient, such as drugs and/or vitamins, contained in a thin film that is attached or placed inside of a pacifier or porous nipple member, such as the tip of a baby bottle.

A. Mark Schobel, President and Chief Executive Officer of MonoSol Rx, stated, “An infant’s natural propensity to suckle makes pacifiers and bottle nipples useful devices for administering medication and vitamins. Affixing a quick dissolving thin film into the porous nipple of a bottle or pacifier ensures that the active ingredient is immediately released into the oral cavity upon contact with saliva or liquid from the bottle. This particular use of thin film allows for a more rapid and uniform delivery of the active compound and increased compliance from caregivers who struggle with administering drugs and vitamins to their infants and small children. Having secured the patent, we are currently looking at potential business development opportunities for this novel thin film drug delivery approach.”

According to the provisions of the patent, the process entails securing a thin film to the inside rim of a pacifier or nipple. The liquid from the bottle or reservoir triggers the release of the active ingredient without requiring the patient to finish the entire bottle for a complete dose. Delivery of a complete and accurate dose is confirmed as the thin film dissolves and disappears from the inside surface of the pacifier or porous nipple. The technology is designed particularly for infants and patients such as the elderly, and those who have had surgery or other illnesses which prevent the ordinary dispensing of medication. The device may be used for veterinary applications as well.

Schobel continued, “Our newest U.S. patent further strengthens our leadership and intellectual property position in thin film drug delivery and development, particularly in difficult-to-treat patient populations. Our robust and growing IP portfolio enables MonoSol Rx to have leadership capabilities in the critical areas of drug taste-masking, film composition, manufacturing, packaging and novel therapeutic film applications.”

About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® technology to deliver drugs in quick dissolving films. PharmFilm® is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs. The Company’s leadership in thin film drug delivery is supported by strong intellectual property, a portfolio of commercialized over-the-counter (OTC) drug products, and a development pipeline of prescription formulations based on PharmFilm® technology. With a vertically integrated development and production infrastructure, MonoSol Rx has the capacity to manufacture OTC drug products for near-term revenues that fund prescription product development programs that will generate long-term value.

The Company’s commercialization strategy for all PharmFilm® products is to partner with the innovator, other specialty pharma or leading consumer products companies that can sell-in and manage product sales and marketing. For existing and future partners, PharmFilm® formulations represent revenue-life cycle extensions for products with patent lives that have expired or are approaching expiration. PharmFilm® is also a tool to help sales and marketing partners differentiate in competitive markets while offering unique advantages over drugs dosed by traditional tablets, capsules and orally disintegrating tablets (ODTs).

Contacts:

The Ruth Group (on behalf of MonoSol Rx):

Jason Rando (media)

(646) 536-7025

jrando@theruthgroup.com

jmccargo@theruthgroup.com

Stephanie Carrington/ Sara Ephraim (investors)

(646) 536-7017/7004

scarrington@theruthgroup.com

sephraim@theruthgroup.com

MonoSol Rx

Keith Kendall

Chief Financial Officer

(732) 564-5000

Please complete this form:

  • To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing info@aquestive.com or by calling 1-908-561-1900.

Please complete the form below and click SEND to receive a copy of “Overcoming Solubility and Permeability Challenges,” a case study detailing the achievements made by Aquestive’s formulation team to create the diazepam buccal film.

  • To subscribe to receive marketing updates about diazepam buccal film and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete the form to receive a demonstration kit for our PharmFilm® technology.

  • To subscribe to receive marketing updates about our PharmFilm® technology and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete this form:

  • To subscribe to receive marketing updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. If for any reason you no longer wish to receive information on Aquestive-sponsored clinical trials, you can contact us at any time by emailing clinicaltrials@aquestive.com.

Whether we are partnering to out license our PharmFilm® technology or in-licensing adjacent assets, Aquestive works hand-in-hand with our partners to address their toughest clinical and business challenges. To learn more, please complete the following form:

  • To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.